Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Problem of Same-Rater Bias

    Research output: Contribution to journalLetterResearchpeer-review

  2. Parent Training for Preschool ADHD in Routine, Specialist Care: A Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Parental Rheumatoid Arthritis and Autism Spectrum Disorders in Offspring: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reappraisal is an effective emotion regulation strategy in children with Tourette syndrome and ADHD

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Biographical disruption or cohesion? How parents deal with their child's autism diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Correction to: Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To investigate cardiometabolic effects and its predictors in youth with first-episode psychosis (FEP) treated with quetiapine-extended release (ER) vs. aripiprazole.

METHOD: Youths with FEP aged 12-17 years were randomized to quetiapine-ER or aripiprazole in the 12-week, double-blinded, Tolerability and Efficacy of Antipsychotics (TEA) trial. Primary outcome was change in body weight; secondary outcomes were changes in body mass index (BMI) and waist circumference (WC), blood pressure (BP), heart rate, and lipid and glucose metabolism parameters. Possible predictors of cardiometabolic changes were examined.

RESULTS: Altogether, 113 patients (schizophrenia-spectrum disorders=93%, age (mean±SD): 15.7±1.4 years, male participants=30.1%), were randomized to quetiapine-ER (n=55) or aripiprazole (n=58). Quetiapine-ER led to significant increases in body weight (4.88 kg, 95% confidence interval (CI): 3.92-5.83, p<.0001), BMI z-score (0.43, 95%CI= 0.33-0.53, p<0.0001) and WC z-score (0.97, CI=0.7-1.23, p<0.0001). Changes were significantly smaller with aripiprazole (all between-group p-values p<0.0001): body weight: 1.97 kg (CI=0.97-2.97, p=0.0001), BMI z-score: 0.10 (CI: -0.01-0.20, p=0.0646) and WC z-score: 0.18 (CI: -0.09-0.45, p=0.1968). Lipid and glucose metabolism parameters increased significantly at week 4 and 12 only with quetiapine-ER (p-range: 0.0001-0.037). Quetiapine-ER was associated with an increased occurrence of obesity, elevated blood lipids and hyperinsulinemia (p-range=0.004-0.039). Early weight gain, obesity or type 2 diabetes in the family significantly predicted weight and BMI gain at week 12.

CONCLUSION: In youth with FEP, quetiapine-ER was associated with significantly greater weight gain and adverse changes in metabolic outcomes than aripiprazole. Early weight gain must be addressed and family lifestyle factors taken into consideration when treating youth with antipsychotics.

Original languageEnglish
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume58
Issue number11
Pages (from-to)1062-1078
Number of pages17
ISSN0890-8567
DOIs
Publication statusPublished - Nov 2019

ID: 56819580